IN THE SPOTLIGHT

Possible Therapeutic Target Identified for Small Cell Lung Cancer

Possible Therapeutic Target Identified for Small Cell Lung Cancer

Durvalumab Shows Improvements in Overall Survival, Progression-Free Survival for Small Cell Lung Cancer

Durvalumab Shows Improvements in Overall Survival, Progression-Free Survival for Small Cell Lung Cancer

Treating Women With Lung Cancer: Screening, Treatment, and Sexual and Reproductive Health

Treating Women With Lung Cancer: Screening, Treatment, and Sexual and Reproductive Health

FDA Grants Fast Track Designation to PT217 for Extensive Stage Small Cell Lung Cancer

FDA Grants Fast Track Designation to PT217 for Extensive Stage Small Cell Lung Cancer

AstraZeneca’s Imfinzi Clinches Late-Stage Victory in Aggressive Lung Cancer

AstraZeneca’s Imfinzi Clinches Late-Stage Victory in Aggressive Lung Cancer

IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

IMFINZI® (durvalumab) significantly improved overall survival and progression-free survival for patients with limited-stage small cell lung cancer in ADRIATIC Phase III trial

AstraZeneca’s lung cancer treatment seen as breakthrough immunotherapy

AstraZeneca’s lung cancer treatment seen as breakthrough immunotherapy

Evolving Strategies in Managing and Treating Small Cell Lung Cancer

Evolving Strategies in Managing and Treating Small Cell Lung Cancer

Lung cancer treatment by stage explained

Lung cancer treatment by stage explained